Jan 16, 2013 company's shares had been redeemed by Oy Lival Ab. Tekla Oyj was company's financial situation. Stockholm. Kancera. 2012-10-16.
Kancera AB: Verkningsmekanismen för Kanceras läkemedelskandidat KAND567 kopplas till minskad risk för allvarliga komplikationer vid covid-19 Publicerad: 2020-07-10 (Cision) Torsdag 9 juli
Existing shareholders had precedence for the issue which was over-subscribed, 161 percent. Kancera AB develops drugs against cancer and inflammatory diseases in laboratories at Karolinska Institutet Science Park in Stockholm and employs approximately 15 people. The share is traded on NASDAQ First North Premier. The number of shareholders as of March 28, 2019 was approxi-mately 7400. FNCA Sweden AB is the company's Certified Adviser. Kancera AB develops drugs against cancer and inflammatory diseases in laboratories at Karolinska Institutet Science Park in Stockholm and employs approximately 15 people. The share is traded on NASDAQ First North Premier.
Avanza Fonder AB is currently the company's largest shareholder with 10% of shares outstanding. With 1.1% and 1.0% of the shares outstanding respectively, Thomas Olin and Håkan Mellstedt are the second and third largest shareholders. KANCERA AB (PUBL) : Company profile, business summary, shareholders, managers, financial ratings, industry, sector and market information | OTC Bulletin Board - Other OTC: KNCQF | OTC Bulletin Board - Other OTC Kancera AB (Publ) develops drugs for inflammatory diseases and cancer in Sweden and internationally. The company is developing small molecule drug candidates KAND567 and KAND145 which block the Fractalkine Kancera AB, Karolinska Institutet Science Park i Stockholm, utvecklar en ny klass av läkemedel mot inflammation och cancer. Kancera har två patentskyddade läkemedelskandidater under klinisk respektive preklinisk utveckling.
Rubrik Av Publicerat; Vad anser ni att aktien är värd om ett halvår?
Kancera's operations are based in the Karolinska Institute Science Park in Stockholm and the company employs around 15 people. Kancera shares are traded on NASDAQ First North and the number of shareholders was more than 7400 as of September 30th, 2018. FNCA is Kancera's Certified Adviser.
In March 2013 Kancera acquired a Kancera AB is a Sweden-based company that develops and sells drug candidates in the field of cancer. The Company's activities are divided into two areas, namely Pharmaceutical Development and Industrial Research and Developme nt (R&D). Pharmaceutical Development area runs such projects, as Project PFKFB3, which aims to develop a drug to combat Kancera shares are traded on NASDAQ First North and the number of shareholders was more than 7400 as of September 30th, 2018.
About Kancera AB (publ) Kancera shares are traded on NASDAQ First North and the number of shareholders was more than 7500 as of June 30th, 2017.
Existing shareholders had precedence for the issue which was over-subscribed, 161 percent. Thomas Olin is the CEO of Kancera AB (publ) (STO:KAN). First, this article will compare CEO compensation with Price trends tend to persist, so it's worth looking at them when it comes to a share like Kancera AB. Over the past six months, the relative strength of its shares against the market has been -99.05%. At the current price of SEK0.002, shares in Kancera AB are trading at % against their 200 day moving average. About Kancera AB (publ) Kancera develops the basis for new therapeutics, starting with new treatment concepts and ending with the sale of a drug candidate to international pharmaceutical companies. Kancera is currently developing drugs for the treatment of leukemia and solid tumors, based on blocking survival signals in the cancer cell and on addressing cancer metabolism. Kancera AB KAN TO 4 - Kancera AB Share Price.
KANCERA AB (PUBL) : Company profile, business summary, shareholders, managers, financial ratings, industry, sector and market information | OTC Bulletin Board - Other OTC: KNCQF | OTC Bulletin Board - Other OTC
Kancera AB (Publ) develops drugs for inflammatory diseases and cancer in Sweden and internationally.
Gms international foods inc
Stockholm. Kancera. 2012-10-16. Interfinans in brief.
Immunicum is establishing a unique immuno-oncology approach through the development of allogeneic,
Jan 16, 2013 company's shares had been redeemed by Oy Lival Ab. Tekla Oyj was company's financial situation.
Tagtider göteborg
Kancera AB Ett svenskt biotechbolag med banbrytande framsteg i sin forskning! It would then pay Acetylon shareholders up to $250 million in
According to the Swedish Companies Act (ABL), all limited companies must A Carlsson Research AB; A&D Engineering, Inc. A-Spine Asia Co., Ltd. Inc. Kalytera Therapeutics Israel, Ltd. Kamada, Ltd. Kamedis Ltd. Kancera AB; Kaneka The largest shareholder was Investor AB with 104,711,363 shares or 17.7% of the share capital (included in nominee register). Shareholders of listed companies Oct 21, 2015 member of Kancera AB. Shareholding: 0. Option holding: 0. Independent: Independent of both the. Company and major shareholders. Note that the company may have other share series admitted to trading and that it may have unlisted shares.